CN115607657A - Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels - Google Patents

Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels Download PDF

Info

Publication number
CN115607657A
CN115607657A CN202210938538.1A CN202210938538A CN115607657A CN 115607657 A CN115607657 A CN 115607657A CN 202210938538 A CN202210938538 A CN 202210938538A CN 115607657 A CN115607657 A CN 115607657A
Authority
CN
China
Prior art keywords
parts
pharmaceutical composition
nattokinase
thrombus
earthworm protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210938538.1A
Other languages
Chinese (zh)
Inventor
赵天
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Enyi Biotechnology Co ltd
Original Assignee
Jiangsu Enyi Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Enyi Biotechnology Co ltd filed Critical Jiangsu Enyi Biotechnology Co ltd
Priority to CN202210938538.1A priority Critical patent/CN115607657A/en
Publication of CN115607657A publication Critical patent/CN115607657A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C12N9/54—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea bacteria being Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21062—Subtilisin (3.4.21.62)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/125—Bacillus subtilis ; Hay bacillus; Grass bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention discloses a pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels, which comprises the following raw materials in parts by weight: 20-30 parts of nattokinase, 20-30 parts of earthworm protein peptide, 10-15 parts of corn starch, 10-15 parts of trehalose and 5-8 parts of magnesium stearate. The medicament contains nattokinase and earthworm protein peptide, wherein the nattokinase has the function of bidirectionally dissolving thrombus, the thrombus dissolving strength is strong, the speed is high, the effect is durable, the earthworm protein peptide can smoothly enter microvasculature to dissolve thrombus in the blood vessel and restore the elasticity of hardened microvasculature, so that the blockage and distortion of the microvasculature are relieved, and the strong direct thrombus dissolving function can be exerted. The combination of the two can realize better efficacy of dissolving thrombus, anticoagulation and purifying blood vessels. And the nattokinase and the earthworm protein do not cause liver burden and do not generate toxic or side effect on human bodies.

Description

Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a thrombolytic anticoagulant blood purification device
Drug combinations of the tubes.
Background
Diseases caused by two pathological processes of thrombosis and thromboembolism are clinically called thrombotic diseases. Thrombotic diseases seriously threaten the life and health of human beings, the incidence rate of the thrombotic diseases is the first of various diseases, and the thrombotic diseases are increasing in recent years, and the thrombotic diseases are one of the key points and hot points of modern medical research. The traditional antithrombotic drugs mainly comprise anticoagulant drugs, antiplatelet drugs and thrombolytic drugs. Although these drugs have a certain effect, the therapeutic effect is single and not ideal.
It is difficult to find that these "garbage" have been accumulated in the blood vessel before the blood vessel is not seriously clogged and no symptoms appear, and only when symptoms of cardiovascular and cerebrovascular diseases appear, people can recognize the severity of the problem, and by this time, it is not easy to remove the blood vessel clogging, one method is to perform surgery, bypass or stent, etc., and the pain and risk of the surgery are well known; the other is to use the medicine, and for hyperlipidemia diseases, statins are used mostly at present, and the medicine has good treatment effect but has certain toxic and side effects on liver and muscle.
Disclosure of Invention
The invention aims to provide a dissolved blood aiming at the defects and shortcomings of the prior art
A pharmaceutical composition for treating thrombosis and blood vessel diseases.
The invention relates to a pharmaceutical composition for dissolving thrombus, anticoagulating blood and purifying blood vessels, which comprises the following raw materials in parts by weight: 20-30 parts of nattokinase, 20-30 parts of earthworm protein peptide, 10-15 parts of corn starch, 10-15 parts of trehalose and 5-8 parts of magnesium stearate.
Further preferably, the pharmaceutical composition for dissolving thrombus, resisting coagulation and purifying blood vessels comprises the following raw materials in parts by weight: 25 parts of nattokinase, 25 parts of earthworm protein peptide, 12 parts of corn starch, 12 parts of trehalose and 6 parts of magnesium stearate.
Preferably, the trehalose and the magnesium stearate are both medicinal grades.
Preferably, the nattokinase is natto freeze-dried powder.
Preferably, the preparation process of the natto freeze-dried powder comprises the following steps:
cleaning semen glycines, decocting in water solution at 100-110 deg.C for 10-35min, and pulverizing; inoculating Bacillus subtilis natto at 25-30 deg.C with the inoculation amount of 1-3%, fermenting at 30-37 deg.C for 20-24 hr to obtain fermented product as nattokinase, and vacuum freeze drying to obtain natto lyophilized powder.
Preferably, the preparation process of the earthworm protein peptide comprises the following steps: mixing the earthworm protein with a citric acid aqueous solution, and extracting for 6-8 h at 15-20 ℃ to obtain an extract liquid; performing solid-liquid separation, and collecting liquid-phase components to obtain an extracted clear solution; sequentially carrying out ultrafiltration and organic membrane filtration on the extracted clear liquid to obtain filtrate; purifying the filtrate by liquid chromatography, and drying to obtain Lumbricus protein peptide.
The preparation method of the pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels comprises the following steps: according to the weight ratio of the raw materials of the pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels, the nattokinase, the earthworm protein peptide, the corn starch, the trehalose and the magnesium stearate are mixed uniformly and then prepared into capsules, tablets or pills.
The invention has the beneficial effects that: the medicament contains nattokinase and earthworm protein peptide, wherein the nattokinase has the function of bidirectionally dissolving thrombus, the thrombus dissolving strength is strong, the speed is high, the effect is durable, the earthworm protein peptide can smoothly enter microvasculature to dissolve thrombus in the blood vessel and restore the elasticity of hardened microvasculature, so that the blockage and distortion of the microvasculature are relieved, and the strong direct thrombus dissolving function can be exerted. The combination of the two can realize better efficacy of dissolving thrombus, anticoagulation and purifying blood vessels.
And the nattokinase and the earthworm protein do not cause liver burden and do not generate toxic or side effect on human bodies.
Detailed Description
The present embodiment will further explain the invention in detail by using the following technical solutions and examples.
Example 1: a pharmaceutical composition for dissolving thrombus, anticoagulation and purifying blood vessels comprises the following raw materials in parts by weight: 20 parts of nattokinase, 20 parts of earthworm protein peptide, 10 parts of corn starch, 10 parts of trehalose and 5 parts of magnesium stearate, and the raw materials are mixed according to the parts by weight and then tabletted to prepare tablets.
Example 2: a pharmaceutical composition for dissolving thrombus, anticoagulation and purifying blood vessels comprises the following raw materials in parts by weight: 30 parts of nattokinase, 30 parts of earthworm protein peptide, 15 parts of corn starch, 15 parts of trehalose and 8 parts of magnesium stearate, and the raw materials are mixed according to the parts by weight and then tabletted to prepare tablets.
Example 3: a pharmaceutical composition for dissolving thrombus, anticoagulation and purifying blood vessels comprises the following raw materials in parts by weight: 25 parts of nattokinase, 25 parts of earthworm protein peptide, 12 parts of corn starch, 12 parts of trehalose and 6 parts of magnesium stearate, and the raw materials are mixed according to the parts by weight and then tabletted to prepare tablets.
The comparative example is a Japanese nattokinase capsule.
The hospital detects patients with symptoms of blood flow disorder such as headache, dizziness, hypertension, hyperlipidemia, etc. Examples 1-3 and comparative examples 1-3 were applied to 600 patients, respectively, and each group of patients was administered for 8 treatment periods, 7 days being one treatment period, and Table 1 shows the effects of patients administered with the drugs prepared in examples 1-3 and comparative examples 1-3 with Japanese nattokinase capsules.
The evaluation standard of curative effect is as follows:
the effect is shown: the symptoms of headache, dizziness, hypertension, hyperlipidemia and the like are obviously improved;
the method has the following advantages: headache, dizziness, hypertension, hyperlipemia and other symptoms are all improved;
and (4) invalidation: headache, dizziness, hypertension, hyperlipemia and other symptoms are not obviously improved.
TABLE 1 comparison of the efficacy of the examples and comparative examples
Figure DEST_PATH_IMAGE001
As can be seen from Table 1, compared with the Japanese nattokinase capsule in the control example, the pharmaceutical composition for dissolving thrombus, resisting coagulation and purifying blood vessels, prepared in the embodiments 1-3 of the invention, has the effects of clearing blood vessels and treating headache, dizziness, hypertension, hyperlipidemia and the like caused by vascular diseases, and is obviously better than the control example.
Therefore, the medicine composition has better effects of dissolving thrombus, resisting blood coagulation and purifying blood vessels.
The foregoing shows and describes the general principles and broad features of the present invention and advantages thereof. It will be understood by those skilled in the art that the present invention is not limited to the embodiments described above, which are described in the specification and illustrated only to illustrate the principle of the present invention, but that various changes and modifications may be made therein without departing from the spirit and scope of the present invention, which fall within the scope of the invention as claimed. The scope of the invention is defined by the appended claims and equivalents thereof.

Claims (7)

1. A pharmaceutical composition for dissolving thrombus, anticoagulating blood and purifying blood vessels is characterized in that: comprises the following raw materials in parts by weight: 20-30 parts of nattokinase, 20-30 parts of earthworm protein peptide, 10-15 parts of corn starch, 10-15 parts of trehalose and 5-8 parts of magnesium stearate.
2. The pharmaceutical composition for thrombolysis, anticoagulation and blood purification according to claim 1, wherein: the medicinal composition for dissolving thrombus, resisting coagulation and purifying blood vessels comprises the following raw materials in parts by weight: 25 parts of nattokinase, 25 parts of earthworm protein peptide, 12 parts of corn starch, 12 parts of trehalose and 6 parts of magnesium stearate.
3. The pharmaceutical composition for thrombolysis, anticoagulation and blood purification according to claim 1, wherein: the trehalose and the magnesium stearate are medicinal grade.
4. The pharmaceutical composition for thrombolysis, anticoagulation and blood purification according to claim 1, wherein: the nattokinase is natto freeze-dried powder.
5. The pharmaceutical composition for thrombolysis, anticoagulation and blood purification according to claim 1, wherein: the preparation process of the natto freeze-dried powder comprises the following steps:
cleaning semen glycines, decocting in water solution at 100-110 deg.C for 10-35min, and pulverizing; inoculating Bacillus subtilis natto at 25-30 deg.C with the inoculation amount of 1-3%, fermenting at 30-37 deg.C for 20-24 hr to obtain fermented product as nattokinase, and vacuum freeze drying to obtain natto lyophilized powder.
6. The pharmaceutical composition for thrombolysis, anticoagulation and blood purification according to claim 1, wherein: the preparation process of the earthworm protein peptide comprises the following steps: mixing the earthworm protein with a citric acid aqueous solution, and extracting for 6-8 h at 15-20 ℃ to obtain an extract liquid; performing solid-liquid separation, and collecting liquid-phase components to obtain an extracted clear solution; sequentially carrying out ultrafiltration and organic membrane filtration on the extracted clear liquid to obtain filtrate; purifying the filtrate by liquid chromatography, and drying to obtain Lumbricus protein polypeptide.
7. The pharmaceutical composition for thrombolysis, anticoagulation and blood purification according to claim 1, wherein: the preparation method of the medicine composition comprises the following steps: according to the weight ratio of the raw materials of the pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels, the nattokinase, the earthworm protein peptide, the corn starch, the trehalose and the magnesium stearate are mixed uniformly and then prepared into capsules, tablets or pills.
CN202210938538.1A 2022-08-05 2022-08-05 Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels Pending CN115607657A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210938538.1A CN115607657A (en) 2022-08-05 2022-08-05 Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210938538.1A CN115607657A (en) 2022-08-05 2022-08-05 Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels

Publications (1)

Publication Number Publication Date
CN115607657A true CN115607657A (en) 2023-01-17

Family

ID=84856983

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210938538.1A Pending CN115607657A (en) 2022-08-05 2022-08-05 Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels

Country Status (1)

Country Link
CN (1) CN115607657A (en)

Similar Documents

Publication Publication Date Title
JP5048673B2 (en) A kind of extract that prevents or treats thrombotic diseases
CN104844723A (en) Preparation method and application of dendrobium officinale extract
DK145505B (en) PROCEDURE FOR PREPARING A NITROGEN CONTAINING POLYSACCHARIDE
NO158101B (en) PROCEDURE FOR THE PREPARATION OF POLYSACCHARIDES WITH ANTI-INFLAMMATORY ACTIVITY.
CN100446779C (en) Method for preparing acanthopanax senticousus extracting liquid/extraction
CN101433553A (en) Method for preparing deproteinized extract of calf blood and freeze-dried powder thereof
US8945633B2 (en) Pharmaceutical composition for preventing and treating inflammatory diseases containing an ethyl acetate fraction of dried extract of Trachelospermi caulis as an active ingredient, and method for producing the fraction
JP4149545B2 (en) Low molecular weight fucans and pharmaceutical compositions thereof
DK145424B (en) PROCEDURE FOR MANUFACTURING NITROGEN CONTAINING POLYSACCHARIDES WITH ANTI-TUMOR-EFFECTIVE
CN115607657A (en) Pharmaceutical composition for dissolving thrombus, resisting blood coagulation and purifying blood vessels
CN101049332A (en) Method for preparing injection preparation of freeze drying powder of Xuesaitong
WO2023186181A1 (en) Application of mulberry extract in preparation of drug for treating ulcerative colitis
CN111588756A (en) Traditional Chinese medicine preparation for treating insomnia, amnesia and neurasthenia and preparation method thereof
CN113813291B (en) Preparation method of animal medicinal material freeze-dried powder
CN1250253C (en) Chinese medicine capsule for treating ischemic cerebral apoplexy
CN109810177A (en) A kind of walnut dregs polypeptide and its preparation method and application with ACE inhibitory activity
CN105796625A (en) Pharmaceutical composition containing red yeast rice and safflower and preparation thereof
JP2010516755A (en) Pharmaceutical composition for prevention and / or treatment of inflammatory diseases, comprising a mixed extract of Tsukiishi wisteria and Ichiyakuso
CN1241923C (en) Method for extracting total alkaloid of corydalis rhizome and its new usage
CN113243532A (en) Natural gel of dietary supplement capable of improving irritable bowel syndrome and preparation method thereof
CN117815335B (en) Osteoarthritis treatment composition based on adipose-derived stem cells SVF and preparation method thereof
CN109485711B (en) Ant lion small-molecule peptide and separation and purification method and application thereof
CN1094291A (en) Houttuynia oral administration liquid
CN108815215B (en) Lu Li grass root water extract and application thereof in reducing blood sugar
CN102552383A (en) Compound jellyfish antihypertensive dispersible tablet and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication